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S Avlund11, TB Olesen12, HJ Hoffmann13, MK Thomsen14, VØ Thomsen15, M Frydenberg16, BA Nexø2, J Sode17,18,19, U Vogel20 and
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Antitumor necrosis factor-a (TNF-a) is used for treatment of severe cases of inﬂammatory bowel diseases (IBD), including Crohn’s
disease (CD) and ulcerative colitis (UC). However, one-third of the patients do not respond to the treatment. Genetic markers may
predict individual response to anti-TNF therapy. Using a candidate gene approach, 39 mainly functional single nucleotide
polymorphisms (SNPs) in 26 genes regulating inﬂammation were assessed in 738 prior anti-TNF-naive Danish patients with IBD. The
results were analyzed using logistic regression (crude and adjusted for age, gender and smoking status). Nineteen functional
polymorphisms that alter the NFkB-mediated inﬂammatory response (TLR2 (rs3804099, rs11938228, rs1816702, rs4696480), TLR4
(rs5030728, rs1554973), TLR9 (rs187084, rs352139), LY96 (MD-2) (rs11465996), CD14 (rs2569190), MAP3K14 (NIK) (rs7222094)), TNF-a
signaling (TNFA (TNF-a) (rs361525), TNFRSF1A (TNFR1) (rs4149570), TNFAIP3(A20) (rs6927172)) and other cytokines regulated by
NFkB (IL1B (rs4848306), IL1RN (rs4251961), IL6 (rs10499563), IL17A (rs2275913), IFNG (rs2430561)) were associated with response to
anti-TNF therapy among patients with CD, UC or both CD and UC (Pp0.05). In conclusion, the results suggest that polymorphisms
in genes involved in activating NFkB through the Toll-like receptor (TLR) pathways, genes regulating TNF-a signaling and cytokines
regulated by NFkB are important predictors for the response to anti-TNF therapy among patients with IBD. Genetically strong TNF-
mediated inﬂammatory response was associated with beneﬁcial response. In addition, the cytokines IL-1b, IL-6 and IFN-g may be
potential targets for treating patients with IBD who do not respond to anti-TNF therapy. These ﬁndings should be examined in
independent cohorts before these results are applied in a clinical setting.
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INTRODUCTION
Inﬂammatory bowel diseases (IBD), including Crohn’s disease (CD)
and ulcerative colitis (UC), are characterized by a dysregulated
inﬂammatory response.1 The transcription factor NFkB is a central
regulator of inﬂammation and regulates the expression of more
than 150 genes including TNFA, TNFAIP3, TLR2, TLR9, CD14, NFKBIA,
NFKB1, IL1B, IL1RN, IL6, IL10, IL17A and IFNG.2 NFkB can be
activated by Toll-like receptors (TLRs), which recognize molecules
that are broadly shared by pathogens but distinguishable from
host molecules, such as bacterial or viral DNA, ﬂagellin or
lipopolysaccharide (LPS). For example, LPS from Gram-negative
bacterial cell membranes can be bound by CD14 in the presence
of LPS-binding protein, which together with MD-2 interacts with
TLR4. TLR4 is a membrane-bound protein, which on LPS stimuli
forms homodimers and activates an intracellular kinase cascade.
This kinase cascade ultimately activates the IKK complex, which
phosphorylates and degrades the NFkB inhibitor IkBa.3 NFkB is
shuttled from the cytosol to the nucleus where it initiates
expression of pro- and anti-inﬂammatory cytokines (Figure 1).
One of the pro-inﬂammatory cytokines activated by NFkB is
tumor necrosis factor-a (TNF-a), whose feedback stimulates NFkB
by binding to TNF receptors (TNFR1 or TNFR2), resulting in a
kinase cascade similar to, but distinct from, the canonical pathway
induced by TLRs.3
The TNF-a level is increased in the blood, stool and intestinal
tissue from patients with CD and UC, and therefore it has been a
target for medical treatment.4–6 Inﬂiximab and adalimumab are
therapeutic antibodies that block the binding of TNF-a to its cell-
surface receptors and limit downstream cell signaling pathways.7
These antibodies are used for the treatment of severe cases of IBD,
but approximately one-third of the patients beneﬁt minimally or
not at all from the treatment.8,9
1Medical Department, Viborg Regional Hospital, Viborg, Denmark; 2Biomedicine, University of Aarhus, Aarhus, Denmark; 3Microbiology and Infection Control, Statens Serum
Institut, Copenhagen, Denmark; 4Department of Gastroenterology, Herlev Hospital, Herlev, Denmark; 5Department of Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark;
6Medical Department, Køge Hospital, Køge, Denmark; 7Medical Department, Hillerød Hospital, Hillerød, Denmark; 8Medical Department, Sydvestjysk Hospital, Esbjerg, Denmark;
9Medical Department, Bispebjerg Hospital, Bispebjerg, Denmark; 10Medical Department, Nykøbing Falster Hospital, Nykøbing Falster, Denmark; 11Medical Department V, Aarhus
University Hospital, Aarhus, Denmark; 12Medical Department, Slagelse Hospital, Slagelse, Denmark; 13Department of Respiratory Diseases B, Institute for Clinical Medicine, Aarhus
University Hospital, Aarhus, Denmark; 14Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark; 15International Reference Laboratory of
Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark; 16Section of Biostatistics, Department of Public health, Aarhus University, Aarhus, Denmark; 17Institute of
Regional Health Research, University of Southern Denmark, Odense, Denmark; 18Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark;
19Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark; 20National Research Centre for the Working Environment, Copenhagen, Denmark; 21Organ
Centre, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark and 22OPEN Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark.
Correspondence: Dr S Bank, Medical Department, Viborg Regional Hospital, Heibergs Alle´ 4, Viborg DK-8800, Denmark.
E-mail: stb@mb.au.dk
Received 21 October 2013; revised 1 March 2014; accepted 10 March 2014; published online 29 April 2014
The Pharmacogenomics Journal (2014) 14, 526–534
& 2014 Macmillan Publishers Limited All rights reserved 1470-269X/14
www.nature.com/tpj
We wanted to investigate whether there were genetic
differences between responders and nonresponders to anti-TNF
therapy among patients with IBD. Therefore, we assessed 39
mainly functional polymorphisms in genes involved in inﬂamma-
tion, in particular the NFkB pathway, in a cohort of 738 Danish IBD
patients previously naive to anti-TNF therapy. Knowing the
biological effect of the studied polymorphisms allows a biological
interpretation of the associations in the candidate genes. The
genes studied are involved in regulation of the NFkB pathway
(TLR2, TLR4, TLR5, TLR9, LY96, CD14, MAP3K14, SUMO4, NFKBIA and
NFKB1), TNF-a signaling (TNFA, TNFRSF1A and TNFAIP3), cytokines
regulated by NFkB (IL1B, IL1RN, IL6, IL10, IL17A and IFNG) and other
genes involved in regulation of inﬂammation (IL4R, IL6R, IL23R,
TGFB1, PTPN22, PPARG and NLRP3).
MATERIALS AND METHODS
Cohort
A prior anti-TNF-naive Danish cohort of patients with IBD was established.
Blood samples retrieved as part of the routine screening for latent
Mycobacterium tuberculosis at Statens Serum Institut (SSI, Copenhagen,
Denmark) and the Department of Respiratory Diseases B, and the
Department Clinical Microbiology, Aarhus University Hospital (Aarhus,
Denmark) were collected from 01 September 2009 to 30 March 2011 (9217
patients). Patients with intestinal diseases (ICD-10 code K50–K63) were
identiﬁed by linking the unique personal identiﬁcation number of Danish
citizens (CPR number) from each blood sample with the National Patient
Registry (2659 patients). Patient records from 18 medical departments
were examined (1378 patients) and identiﬁed 738 previously anti-TNF-
naive ethnic Danish patients with IBD. Treatment efﬁcacy using the simple
three-step scale10–12 reﬂected the maximum response within 22 weeks
after initiation.
Genotyping
DNA was extracted from cryopreserved blood clots by using the Maxwell
16 Blood puriﬁcation kit (Promega, Madison WI, USA) according to the
manufacturers’ instructions with a median yield of 4.90 mg (range 0.8–
25mg) per 300ml total blood.13 Competitive Allele-Speciﬁc Polymerase
chain reaction (KASP), an end-point PCR technology, was used by LGC
Genomics for genotyping (LGC Genomics, Hoddesdon, UK) (http://
www.lgcgenomics.com/).
The single nucleotide polymorphisms (SNPs) studied were TLR2
(rs4696480, rs1816702, rs11938228, rs3804099), TLR4 (rs12377632,
rs5030728, rs1554973), TLR5 (rs5744168), TLR9 (rs187084, rs352139), LY96
(MD-2) (rs11465996), CD14 (rs2569190), MAP3K14 (NIK) (rs7222094), SUMO4
(rs237025), NFKBIA (IkBa) (rs696, rs17103265), NFKB1 (NFkB1) (rs28362491),
TNFA (TNF-a) (rs1800629, rs1800630, rs1799724, rs361525), TNFRSF1A
(TNFR1) (rs4149570), TNFAIP3 (A20) (rs6927172), IL1B (IL-1b) (rs1143623,
rs4848306, rs1143627), IL1RN (IL-1RA) (rs4251961), IL4R (rs1805010),
Figure 1. Simplified overview of the NFkB pathway highlighting the genes that were studied. Polymorphisms in genes associated or not
associated with response to anti-TNF therapy among patients with IBD are written in white and red, respectively. Genes not studied are
written in black. Increased gene/protein activity was associated with beneficial response (green) or nonresponse (purple). The biological effect
was unclear (TLR4, TLR9, NIK) or showed opposite direction of effect among patients with CD and UC (MD-2) (blue). A significant association
was only seen in CD14 and IL-1RA (inhibitor of IL-1b signaling) among patients with UC. CD, Crohn’s disease; IBD, inflammatory bowel disease;
UC, ulcerative colitis.
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IL6 (rs10499563), IL6R (rs4537545), IL10 (rs1800872, rs3024505), IL17A
(rs2275913), IL23R (rs11209026), IFNG (IFN-g) (rs2430561), TGFB1 (TGF-b1)
(rs1800469), PTPN22 (rs2476601), PPARG (PPAR-g) (rs1801282) and NLRP3
(rs4612666).
Genotyping of TNFA (TNF-a) –857 C4T (rs1799724) and –863 C4A
(rs1800630) failed due to their close proximity to each other. All
genotyping of –857 C4T (rs1799724) either failed or were erroneously
genotyped as homozygous wild type when the patients were carriers of
the AA genotype of –863 C4A (rs1800630) due to genotyping bias.
The 39 SNPs were replicated in 94 randomly selected samples and
yielded 499% identical genotypes. The studied SNPs had a minor allele
frequency of 0.05–0.48.
Linkage disequilibrium was calculated using the Genome-wide LInkage
DisEquilibrium Repository and Search Engine (GLIDER) software (http://
www.sanger.ac.uk/resources/software/gliders/). Haplotypes were inferred
manually.
Ethical considerations
The study was conducted in accordance with the Declaration of Helsinki
and was approved by the local regional ethics committees (M20100153
and S-20120113) and the Danish Data Protection Agency (J. 2010-41-4719
and 2008-58-035).
Power analysis
The Genetic Power Calculator was utilized for power analysis of discrete
traits.14 The ‘high-risk allele frequency’ was set to 0.05, 0.25 and 0.48, the
‘prevalence’ was set to 0.33, D-prime was set to 1, type I error rate was set
to 0.05 and number of cases and control:case ratio was based on Table 1.
This cohort study had more than 80% chance of detecting a dominant
effect with an odds ratio (OR) of 1.9, 1.5 and 1.6 for CD, 2.1, 1.7 and 1.9 for
UC and 1.6, 1.4 and 1.5 for IBD with high-risk allele frequencies of 0.05, 0.25
and 0.48, respectively.
Statistical analysis
Logistic regression, crude and adjusted for age, gender and smoking
status, was used to compare genotypes among responders versus
nonresponders and responders versus non- and partial responders to
anti-TNF therapy (Supplementary Tables 1–3).
A w2-test or unpaired t-test was used to test for statistically signiﬁcant
difference in response between patients with CD and UC, for difference in
secondary parameters between responders and nonresponders (Table 1),
and for haplotype analysis (Supplementary Tables 4–7).
To achieve more statistical power, analyses for associations between
polymorphisms and treatment response in relation to IBD and for
haplotype analyzed were performed with the combined CD and UC data
set.
Statistical analyses were performed using STATA version 11 (STATA,
College Station, TX, USA).
RESULTS
Study population
The clinical and demographic characteristics of the 482 and 256
prior anti-TNF-naive patients with CD and UC, respectively, are
shown in Table 1. More females (17%) than males (9%) were
nonresponders among patients with CD (OR: 2.05, 95% CI: 1.16–
3.64, P¼ 0.01) and a decrease in CRP level by more than 25% was
associated with beneﬁcial response among patients with IBD
when only considering CRPX20mg l 1 pretreatment (OR: 2.01,
95% CI: 1.09–3.72, P¼ 0.02). Furthermore, 14% (66 patients) and
24% (62 patients) were nonresponders among patients with CD
and UC, respectively (OR: 0.48, 95% CI: 0.33–0.72, P¼ 0.001).
Young age at diagnosis was borderline associated with beneﬁcial
response (P¼ 0.06).
Polymorphisms associated with response in CD
In a dominant model, the homozygous variant genotype of
TNFRSF1A –609G4T (rs4149570) (ORadj: 2.39, 95% CI: 1.03–5.57,
P¼ 0.04), the heterozygous genotype of TLR4 G4A (rs5030728)
(ORadj: 3.34, 95% CI: 1.32–8.47, P¼ 0.01) and both the homozygous
and the heterozygous variant genotypes of TLR2 597T4C
(rs3804099) (ORadj: 2.02, 95% CI: 1.17–3.49, P¼ 0.01), TLR2 C4T
(rs1816702) (ORadj: 2.02, 95% CI: 1.04–3.95, P¼ 0.04), LY96 (MD-2) –
1625 C4G (rs11465996) (ORunadj: 1.73, 95%CI: 1.01–2.95, P¼ 0.04)
and IFNG 874T4A (rs2430561) (ORadj: 1.97, 95% CI: 1.13–3.42,
P¼ 0.02) were associated with beneﬁcial response among patients
with CD (Supplementary Table 1).
In a recessive model, the homozygous variant genotypes of
TLR4 G4A (rs5030728) (ORadj: 0.38, 95% CI: 0.15–0.96, P¼ 0.04)
and TLR9 1174G4A (rs352139) (ORadj: 0.38, 95% CI: 0.16–0.94,
P¼ 0.04) were associated with nonresponse and the homozygous
variant genotype of TNFRSF1A –609G4T (rs4149570) (ORadj: 5.16,
95% CI: 1.14–23.39, P¼ 0.03) was associated with beneﬁcial
response among patients with CD (Supplementary Table 1).
The variant allele of the polymorphisms has been shown to
decrease TNF-a, IL-1b and IL-6 levels (TLR2 597T4C (rs3804099)),
increase TLR2 (TLR2 C4T (rs1816702)), MD-2 and TNF-a levels
(LY96 –1625 C4G (rs11465996)), increase TNFRSF1A expression
(TNFRSF1A –609G4T (rs4149570)) and decrease IFN-g level (IFNG
874T4A (rs2430561)) (Table 2).
The biological effect of the polymorphism TLR4 G4A
(rs5030728) and TLR9 1174G4A (rs352139) was unknown.
Thus, genetically determined increased TLR2 level (rs1816702),
MD-2 level (rs11465996), TNFRSF1A (TNFR1) expression (rs4149570)
and genetically determined decreased IL-1b (rs3804099), IL-6
(rs3804099) and IFN-g (rs2430561) levels were associated with
beneﬁcial response among patients with CD. The genetically
determined effect of TNF-a was inconclusive among patients with
CD, as one polymorphism indicated that genetically determined
increased TNF-a level (rs11465996) and another polymorphism
indicated that decreased TNF-a level (along with decreased IL-1b
and IL-6 levels) (rs3804099) were associated with beneﬁcial
response.
Polymorphisms associated with response in UC
In a dominant model, the homozygous variant genotype of TLR4
G4A (rs5030728) (ORunadj: 2.89, 95% CI: 1.17–7.12, P¼ 0.02) and
both the homozygous and the heterozygous variant genotypes
of IL1B –3737G4A (rs4848306) (ORadj: 2.69, 95% CI: 1.04–6.94,
P¼ 0.04) and IL6 –6331T4C (rs10499563) (ORadj: 3.60, 95% CI:
1.39–9.29, P¼ 0.01) were associated with beneﬁcial response
among patients with UC. The homozygous variant genotype of
TLR2 A4T (rs4696480) (ORunadj: 0.47, 95% CI: 0.23–0.95, P¼ 0.04)
and both the homozygous and the heterozygous variant
genotypes of TLR2 C4A (rs11938228) (ORunadj: 0.49, 95% CI:
0.26–0.90, P¼ 0.02), LY96 (MD-2) –1625 C4G (rs11465996) (ORadj:
0.32, 95% CI: 0.14–0.75, P¼ 0.01), CD14 –159G4A (rs2569190)
(ORunadj: 0.54, 95% CI: 0.30–0.98, P¼ 0.04), TNFAIP3 (A20) C4G
(rs6927172) (ORadj: 0.34, 95% CI: 0.13–0.90, P¼ 0.03), IL1RN T4C
(rs4251961) (ORadj: 0.42, 95% CI: 0.18–0.98, P¼ 0.04) and IL17A
197G4A (rs2275913) (ORadj: 0.42, 95% CI: 0.18–1.00, P¼ 0.05)
were associated with nonresponse (Supplementary Table 2).
In a recessive model, the homozygous variant genotype of TLR2
597T4C (rs3804099) (ORunadj: 2.47, 95% CI: 0.98–6.23, P¼ 0.05)
and the homozygous variant genotype of TLR4 G4A (rs5030728)
(ORunadj: 2.59, 95% CI: 1.08–6.18, P¼ 0.03) were associated with
beneﬁcial response among patients with UC. The homozygous
variant genotype of TLR2 C4A (rs11938228) (ORadj: 0.26, 95% CI:
0.08–0.92, P¼ 0.04) and the homozygous variant genotype of TLR2
A4T (rs4696480) (ORadj: 0.29, 95% CI: 0.12–0.70, P¼ 0.01) were
associated with nonresponse (Supplementary Table 2).
The variant allele of the polymorphisms has been shown to
decrease TNF-a, IL-1b and IL-6 levels (TLR2 597T4C (rs3804099)),
increase MD-2 and TNF-a levels (LY96 –1625 C4G (rs11465996)),
CD14 level (CD14 –159G4A (rs2569190)), increase TNFAIP3
expression (TNFAIP3 C4G (rs6927172)), decrease IL1B transcrip-
tion (IL1B –3737G4A (rs4848306)), decrease IL-1RA level
SNPs associated with anti-TNF response
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Table 1. Clinical and demographic characteristics for antitumor necrosis factor alpha (TNF-a)-naive inflammatory bowel disease patients treated with anti-TNF
Characteristics CD UC IBD
Responders Nonresponders Non- and
partial
responders
P-value Responders Nonresponders Non- and
partial
responders




Efficacy—no. (%) 355 (74) 66 (14) 127 (26) — 163 (64) 62 (24) 93 (36) — 518 (70) 128 (17) 220 (30) —
Gender—no. (%)
Male 161 (78) 19 (9) 46 (22) 81 (65) 27 (22) 44 (35) 242 (73) 46 (14) 90 (27)




24 (7–77) 27 (14–70) 25 (10–70) 0.11 31 (12–81) 31 (11–77) 31 (4–77) 0.80 26 (7–81) 29 (11–77) 27 (4–77) 0.06
Location—no. (%)
Ileal (L1) 90 (25) 24 (36) 36 (28) 0.07 — — — — — — — —
Colonic (L2) 121 (34) 23 (35) 47 (37) 1.00 — — — — — — — —
Ileocolonic (L3) 127 (36) 15 (23) 37 (29) 0.05 — — — — — — — —
Distribution—no. (%)
Proctitis (E1) — — — — 21 (13) 14 (23) 17 (18) 0.10 — — — —
Left side (E2) — — — — 76 (47) 28 (45) 42 (45) 0.88 — — — —
Extensive (E3) — — — — 53 (33) 15 (24) 22 (24) 0.26 — — — —
Data not available 17 (5) 4 (6) 7 (6) — 13 (8) 5 (8) 12 (13) — — — — —
Smoking history—no. (%)
Current smoker 99 (28) 22 (33) 43 (34) 0.46 18 (11) 1 (2) 2 (2) 0.03 117 (23) 23 (18) 45 (20) 0.14
Former smoker 39 (11) 5 (8) 12 (9) 0.51 36 (22) 13 (21) 20 (22) 1.00 75 (14) 18 (14) 32 (15) 1.00
Never smoker 92 (26) 11 (17) 32 (25) 0.12 39 (24) 13 (21) 19 (20) 0.60 131 (25) 24 (19) 51 (23) 0.11
Data not available 125 (35) 28 (42) 40 (31) — 70 (43) 35 (56) 52 (56) — 195 (38) 63 (49) 92 (42) —
Concomitant medication—no. (%)
Azathioprine 102 (29) 15 (23) 42 (33) 0.37 29 (18) 13 (21) 21 (23) 0.70 131 (25) 28 (22) 63 (29) 0.43
5-aminosalicylates 28 (8) 5 (8) 7 (6) 1.00 61 (37) 24 (39) 33 (35) 0.88 89 (17) 29 (23) 40 (18) 0.16
Glucocorticoids 105 (30) 24 (36) 45 (35) 0.31 83 (51) 31 (50) 43 (46) 1.00 188 (36) 55 (43) 88 (40) 0.19
Methotrexate 5 (1) 0 (0) 3 (2) — 1 (1) 0 (0) 1 (1) — 6 (1) 0 (0) 4 (2) —
Antibiotics 22 (6) 5 (8) 13 (10) 0.78 15 (9) 6 (10) 10 (11) 1.00 37 (7) 11 (9) 23 (10) 0.71
CRP—no. (%)
X25% decrease in
CRP within 22 weeks.
Baseline CRP X20mg l 1
66 (19) 7 (11) 20 (16) 0.16 30 (18) 6 (10) 9 (10) 0.15 96 (19) 13 (10) 29 (13) 0.02






























Table 2. The biological effect of the studied SNP, OR and association with anti-TNF therapy among patients with CD, UC and combined IBD
Gene (SNP) rs number Effect of the SNP OR (95% CI) Association
TLR2 (activates inflammation through the canonical NFkB pathway)
A4T rs4696480 Unknown38 0.47 (0.23–0.95)c Nonresponse (TT)c
C4A rs11938228 Unknown38 0.63 (0.41–0.98)a Nonresponse (CA or AA)a,c
C4T rs1816702 rs1816702T increases receptor levele,16 2.02 (1.04–3.95)b Response (CT or TT)b
597T4C rs3804099 597C decreases TNF-a, IL-1b and IL-6 levelsg,36 1.80 (1.15–2.81)a Response (TC or CC)a,b,c
TLR4 (activates inflammation through the canonical or noncanonical NFkB pathway)
G4A rs5030728 Unknown38 1.45 (1.06–2.00)a Response (GA or AA)a,b,c
T4C rs1554973 Unknown38 0.72 (0.52–0.99)a Nonresponse (TC or CC)a
T4C rs12377632 Unknown38 — No association
TLR5 (activates inflammation through the canonical NFkB pathway)
1174C4T rs5744168 1174T (392STOP) decreases TNF-a, IL-1b and
IL-6 levelg,36 and inhibits TLR5 functionf,g,39
— No association
TLR9 (activates inflammation through the canonical NFkB pathway)
–1486T4C rs187084 –1486C and 1174G decrease expressionf,19 1.99 (1.04–3.82)a Response (TC)a
1174G4A rs352139 –1486C and 1174G decrease expressionf,19 0.48 (0.24–0.96)a Nonresponse (AA)a,b
LY96 (MD-2 binds to TLR2 or TLR4 and is required for their activation to LPS stimuli)
–1625C4G rs11465996 –1625G increases MD-2 and TNF-a levelsf,g,15 1.48 (1.00–2.19)a Response (CG or GG)a,b,c,d
CD14 (binds LPS and transport it to TLR4)
–159G4A rs2569190 –159AA increases CD14 levelg,17,18 0.54 (0.30–0.98)c Nonresponse (GA or AA)c
MAP3K14 (NIK is a central kinase in the noncanonical NFkB pathway)
T4C rs7222094 rs7222094CC decreases NIK activityg,21 1.92 (1.00–3.68)a Response (TC)a
SUMO4 (SUMO4 conjugates to IkBa and negatively regulates NFkB transcriptional activity)
163T4C rs237025 163C increases NFkB1 expressionf,40 — No association
NFKBIA (IkBa is an inhibitor of NFkB1)
2758A4G rs696 2758A increases expressionf,41 — No association
T4del rs17103265 rs17103265del decreases expressionf,42 — No association
NFKB1 (NFkB1 (p50-RelA) is a transcription factor)
–94 ins per del rs28362491 –94del decreases expressionf,i,43 — No association
TNFA (TNF-a is a pro-inflammatory cytokine activated by NFkB1)
–863C4A rs1800630 –863A increases expressionf,i,44 — Failed to genotype
–857C4T rs1799724 –857T increases TNF-a levelf,g,h,45 — Failed to genotype
–308G4A rs1800629 –308A increases expressione,f,46 — No association
–238G4A rs361525 –238A decreases expressionf,g,25 0.43 (0.19–0.97)a Nonresponse (GA)a
TNFRSF1A (TNF receptor 1 (TNFR1) binds TNF-a and initiates a kinase cascade)
–609G4T rs4149570 –609T increases expressionh,47 2.07 (1.03–4.15)a Response (TT)a,b
TNFAIP3 (TNF-a rapidly induced expression of TNFAIP3 (A20) that inhibit NFkB activation and TNF-a mediated apoptosis)
C4G rs6927172 rs6927172G increases expressionf,i,27 0.62 (0.42–0.92)a Nonresponse (CG or GG)a,c
IL1B (pro-inflammatory cytokine activated by NFkB1)
–3737G4A rs4848306 –3737A decreases transcriptionh,26,29 1.85 (1.05–3.27)a Response (GA or AA)a,c
–1464G4C rs1143623 rs1143623C decreases IL-1b levelg,26,32 — No association
–31T4C rs1143627 –31C decreases expressionf,g,i,26,31,32 — No association
IL1RN (IL-1RA binds to the IL-1 receptor and inhibits IL-1b signaling)
T4C rs4251961 rs4251961C decreases IL-1RA levelg,33,48 0.42 (0.18–0.98)c Nonresponse (TC or CC)c
IL4R (IL-4 receptor, IL-4 significantly inhibits IL-17 production)
A4G (I50V) rs1805010 rs1805010G increases IL-17 levele,g,49 — No association
SNPs associated with anti-TNF response
S Bank et al
530
The Pharmacogenomics Journal (2014), 526 – 534 & 2014 Macmillan Publishers Limited
(IL1RN T4C (rs4251961)), decrease IL6 expression (IL6 –6331T4C
(rs10499563)) and increase IL17A expression (IL17A 197G4A
(rs2275913)) (Table 2). The biological effect of the polymorphisms
TLR2 A4T (rs4696480), TLR2 C4A (rs11938228) and TLR4 G4A
(rs5030728) was unknown.
Thus, genetically determined increased MD-2 level
(rs11465996), CD14 level (rs11465996), TNF-a level (rs11465996),
TNFAIP3 (A20) expression (rs6927172) and IL-17 expression
(rs2275913) were associated with nonresponse and genetically
determined decreased IL1B (rs4848306 and rs3804099) and IL6
expressions (rs10499563 and rs3804099) were associated with
beneﬁcial response among patients with UC. One polymorphism
indicated that decreased TNF-a level (along with decreased IL-1b
and IL-6 levels) (rs3804099) was associated with beneﬁcial
response. Finally, genetically determined decreased IL-1RA level
(rs4251961) was associated with nonresponse.
Polymorphisms associated with response in CD and UC combined
(IBD)
The polymorphisms generally showed the same direction of effect
in both diseases, except for the polymorphisms in LY96
(rs11465996) (Supplementary Tables 1 and 2).
In a dominant model, the homozygous variant genotype of
TNFRSF1A –609G4T (rs4149570) (ORadj: 2.07, 95% CI: 1.03–4.15,
P¼ 0.04), the heterozygous genotypes of TLR9 –1486T4C
(rs187084) (ORadj: 1.99, 95% CI: 1.04–3.82, P¼ 0.04) and MAP3K14
T4C (rs7222094) (ORadj: 1.92, 95% CI: 1.00–3.68, P¼ 0.05) and
both the homozygous and the heterozygous variant genotypes of
TLR2 597T4C (rs3804099) (ORadj: 1.80, 95% CI: 1.15–2.81, P¼ 0.01),
TLR4 G4A (rs5030728) (ORunadj: 1.45, 95% CI: 1.06–2.00, P¼ 0.02),
LY96 (MD-2) –1625 C4G (rs11465996) (ORunadj: 1.48, 95% CI: 1.00–
2.19, P¼ 0.05), IL1B –3737G4A (rs4848306) (ORadj: 1.85, 95% CI:
1.05–3.27, P¼ 0.03), IL6 –6331T4C (rs10499563) (ORadj: 2.26, 95%
CI: 1.18–4.32, P¼ 0.01) and IFNG 874T4A (rs2430561) (ORadj: 1.66,
95% CI: 1.05–2.62, P¼ 0.03) were associated with beneﬁcial
response among patients with IBD. The heterozygous genotype
of TNFA –238G4A (rs361525) (ORadj: 0.43, 95% CI: 0.19–0.97,
P¼ 0.04) and both the homozygous and the heterozygous variant
genotypes of TLR2 C4A (rs11938228) (ORadj: 0.63, 95% CI: 0.41–
0.98, P¼ 0.04), TLR4 T4C (rs1554973) (ORunadj: 0.72, 95% CI: 0.52–
0.99, P¼ 0.04) and TNFAIP3 (A20) C4G (rs6927172) (ORadj: 0.62,
95% CI: 0.42–0.92, P¼ 0.02) were associated with nonresponse
(Supplementary Table 3).
In a recessive model, the homozygous variant genotype of TLR2
597T4C (rs3804099) (ORadj: 2.52, 95% CI: 1.08–5.87, P¼ 0.03) and
the homozygous variant genotype of TNFRSF1A –609G4T
(rs4149570) (ORadj: 2.65, 95% CI: 1.00–6.97, P¼ 0.05) were
associated with beneﬁcial response. The homozygous variant
genotype of TLR9 1174G4A (rs352139) (ORadj: 0.48, 95% CI: 0.24–
0.96, P¼ 0.04) and the homozygous variant genotype of IL17A
197G4A (rs2275913) (ORadj: 0.47, 95% CI: 0.21–1.01, P¼ 0.05)
were associated with nonresponse (Supplementary Table 3).
Table 2. (Continued)
Gene (SNP) rs number Effect of the SNP OR (95% CI) Association
IL6 (pro- and anti-inflammatory cytokine activated by NFkB1)
–6331T4C rs10499563 –6331C decreases expressionf,i,30 2.26 (1.18–4.32)a Response (TC or CC)a,c
IL6R (binds IL-6 and initiates a kinase cascade)
C4T rs4537545 rs4537545TT increases IL-6r and IL-6
levels but not TNF-a, IL-1RA and CRP levelsg,34
— No association
IL10 (activated by NFkB1, capable of inhibiting synthesis of pro-inflammatory cytokines such as IFN-g and TNF-a)
–592 C4A rs1800872 –592A increases expressionf,50 — No association
C4T rs3024505 Unknown. Associated with IBD51 — No association
IL17A (activated by NFkB1, pro-inflammatory, potent mediator in delayed-type reactions, induces production of IL-1b, IL-6 and TNF-a)
197G4A rs2275913 197A increases expressionf,h,i,37 0.42 (0.18–1.00)c Nonresponse (GA or AA)a,c
IL23R (IL-23 receptor, IL-23 induces the production of IL-17 and IFN-g)
G4A (R381Q) rs11209026 rs11209026GG increases IL-17 serum levelg,52 — No association
IFNG (IFN-g is a pro- and anti-inflammatory cytokine activated by NFkB1)
874T4A rs2430561 874A decreases IFN-g levelg,28 1.66 (1.05–2.62)a Response (TA or AA)a,b
TGFB1 (TGF-b1 is a cytokine that can inhibit the secretion and activity of many other cytokines including IFN-g and TNF-a)
–509C4T rs1800469 –509T increases expressionf,i,53 — No association
PTPN22 (involved in several signaling pathways associated with the immune response)
1858G4A rs2476601 1858A decreases TNF-a in serumg,h,54 — No association
PPARG (PPARg is a transcription factor)
C4G rs1801282 rs1801282G decreases PPARg mRNA
level, but upregulates MyD88 TLR4, TLR5,
TLR9, P65 and TNF-a mRNA levelsg,h,55
— No association
NLRP3 (NALP3 is involved in the inflammasome)
C4T rs4612666 rs4612666T decreases expressionf,56 — No association
Abbreviations: CD, Crohn’s disease; CI, confidence interval; CRP, C-reactive protein; IBD, inflammatory bowel disease; LPS, lipopolysaccharide; OR, odds ratios;
SNP, single nucleotide polymorphism; UC, ulcerative colitis. aAssociation among patients with IBD. bAssociation among patients with CD. cAssociation among
patients with UC. dThe polymorphism showed opposite direction of effect among patients with CD and UC. eFunction examined by flow cytometry. fFunction
examined by luciferase reporter assay. gFunction examined by enzyme-linked immunosorbent assay. hFunction examined by reverse transcriptase PCR.
iFunction examined by electrophoretic mobility shift assay.
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The variant allele of the polymorphisms has been shown to
decrease TNF-a, IL-1b and IL-6 levels (TLR2 597T4C (rs3804099)),
increase MD-2 and TNF-a levels (LY96 –1625 C4G (rs11465996)),
decrease TNFA expression (TNFA –238G4A (rs361525)), increase
TNFRSF1A (TNFRSF1A –609G4T (rs4149570)), TNFAIP3 expressions
(TNFAIP3 C4G (rs6927172)), decrease IL1B transcription (IL1B –
3737G4A (rs4848306)), decrease IL6 expression (IL6 –6331T4C
(rs10499563)), increase IL17A expression (IL17A 197G4A
(rs2275913)) and decrease IFN-g level (IFNG 874T4A (rs2430561))
(Table 2). The polymorphisms –1486T4C (rs187084) and
1174G4A (rs352139) in TLR9 have only been shown to have a
biological effect in a haplotype context and the biological effect of
the heterozygous variant of MAP3K14 T4C (rs7222094) was
unknown. The biological effect of the polymorphisms TLR2 C4A
(rs11938228), TLR4 G4A (rs5030728) and TLR4 T4C (rs1554973)
was unknown.
Thus, genetically determined increased MD-2 level (rs11465996)
and TNFRSF1A (TNFR1) expression (rs4149570) and genetically
determined decreased TNFAIP3 (A20) expression (rs6927172), IL-1b
(rs3804099 and rs4848306), IL-6 (rs3804099 and rs10499563), IL-17
(rs2275913) and IFN-g (rs2430561) levels were associated with
beneﬁcial response among patients with IBD. Again, the effect of
TNF-a was less clear, as two polymorphisms indicated that
genetically determined increased TNF-a level (rs11465996 and
rs361525) and one polymorphism indicated that decreased TNF-a
level (rs3804099) (along with decreased IL-1b and IL-6 levels) were
associated with beneﬁcial response.
Haplotype analysis
Haplotype analysis of TLR2, TLR4, TLR9 and IL1B among patients
with IBD is shown in Supplementary Tables 4–7, respectively.
Rs11938228 and rs3804099 in TLR2 were in linkage disequilibrium
with r2¼ 0.34 and D’¼ 1.00. In TLR9, the linkage disequilibrium for
rs187084 and rs352139 was r2¼ 0.55 and D’¼ 1.00.
Four haplotypes in TLR2, three in TLR4 and IL1B and two in TLR9
described 85, 95, 99 and 97% of the genotypes observed,
respectively. The TLR2 haplotype 22 (rs4696480TT, rs1816702CC,
rs11938228AA and rs3804099TT) (OR: 0.41, 95% CI: 0.19–0.86,
P¼ 0.02) and the haplotype 12 (rs4696480TA, rs1816702CC,
rs11938228CA and rs3804099CT) (OR: 0.48, 95% CI: 0.24–0.95,
P¼ 0.04) were associated with nonresponse. Haplotype combina-
tion 33 was also associated with nonresponse, although not
statistically signiﬁcant. Both haplotypes 2 and 3 encompass the
wild-type allele of rs3804099, and thus the haplotype analysis
supports the found association between the variant allele of
rs3804099 and beneﬁcial response. No associations were found for
TLR4,TLR9 or IL1B.
DISCUSSION
In the inﬂammatory pathways, 37 SNPs in 26 genes were
successfully genotyped and 19 of the functional polymorphisms
in 14 genes were associated with response to anti-TNF therapy
among patients with CD, UC, or CD and UC combined (IBD) as
shown in Figure 2.
As illustrated in Figure 1, genetically determined increased
levels of TLR2 (rs1816702) and MD-2 (LY96) (rs11465996) (required
for TLR2 and TLR4 to respond to LPS)15,16 were associated with
beneﬁcial response among patients with CD, indicating that a
higher activity of TLR2 was associated with a beneﬁcial response
among patients with CD. Among patients with UC, genetically
determined increased levels of MD-2 (LY96) (rs11465996) and
CD14 (rs2569190)15,17,18 were associated with nonresponse,
indicating that a high activity of TLR4 was associated with nonres-
ponse among patients with UC. In addition, two SNPs in TLR2
(rs4696480 and rs11938228) and two SNPs in TLR4 (rs5030728 and
rs1554973) with unknown biological effects were associated with
response among patients with CD, UC or IBD as shown in Table 2.
The TLR9 heterozygous genotype of –1486T4C (rs187084) and
the homozygous variant genotype of TLR9 1174G4A (rs352139)
were associated with beneﬁcial response and nonresponse among
patients with IBD, respectively. The 1486T4C and 1174G4A
polymorphisms in TLR9 have only been shown to have a biological
effect in haplotype context,19,20 however, the haplotype analysis
of TLR9 did not reveal any associations. Thus, the results indicate
that TLR activity is important in determining response to anti-TNF
therapy among patients with IBD.
Regarding the canonical and noncanonical NFkB pathway,
functional polymorphisms in SUMO4, NFKBIA (IkBa) and NFKB1
(p50-RelA) were not found to be associated with response.
However, the heterozygous genotype of rs7222094 T4C in
MAP3K14 (NIK) was associated with beneﬁcial response among
patients with IBD. The biological effect of the heterozygous
genotype is unknown,21 which makes it difﬁcult to interpret the
association in MAP3K14 from a biological perspective. Further
studies of the noncanonical NFkB pathway, for example, by
studying functional polymorphisms in LTA or TNFSF11 (RANKL),22–24
could shed more light on any possible involvement of this
pathway in anti-TNF therapy response.
The TNF-a signaling pathway showed that a genetically
determined decreased expression of TNFA (TNF-a) (rs361525)25
was associated with nonresponse among patients with IBD.
Furthermore, a genetically determined increased expression of
the TNF receptor 1 (TNFRSF1A) (rs4149570)26 was associated with
beneﬁcial response among patients with CD and IBD. In addition, a
genetically determined increased expression of TNFAIP3 (A20)
(rs6927172)27 was associated with nonresponse among patients
with IBD. A20, encoded by TNFAIP3, is known to inhibit NFkB
activation as well as TNF-a-mediated apoptosis.
Thus, the results indicate that polymorphisms in TNFA (TNF-a),
TNFRSF1A (TNFR1) and TNFAIP3 (A20), which upregulate TNF-a
Figure 2. Polymorphisms associated with response to anti-TNF.
Thirty-seven functional single nucleotide polymorphisms (SNPs) in
26 genes were successfully genotyped and 19 SNPs in 14 genes
were associated with response to antitumor necrosis factor-a (TNF-
a) therapy among patients with Crohn’s disease (CD), ulcerative
colitis (UC) or CD and UC combined. The 19 SNPs associated with
response were in genes involved in regulation of NFkB through the
Toll-like receptor (TLR) pathways (TLR2, TLR4, TLR9, LY96 (MD-2), CD14
and MAP3K14 (NIK)), TNF-a signaling (TNFA (TNF-a), TNFRSF1A
(TNFR1) and TNFAIP3 (A20)) or cytokines regulated by NFkB (IL1B,
IL1RN, IL6, IL17A and IFNG).
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signaling, were associated with beneﬁcial response to anti-TNF
therapy among patients with IBD.
Among cytokines regulated by NFkB, a genetically determined
decreased expression of IL1B (rs4848306), IL6 (rs10499563) and
IFNG (rs2430561)28–30 were associated with beneﬁcial response
among patients with CD, UC and IBD. Furthermore, a poly-
morphism in IL1B (rs1143627), which has been shown to increase
IL-1b level,31,32 was borderline signiﬁcantly associated with
nonresponse among patients with IBD. In addition, a genetically
determined decreased IL-1 receptor antagonist (IL-1RA) level
(rs4251961)33 was associated with nonresponse among patients
with UC. IL-1RA binds to the IL-1 receptor and inhibits IL-1b
signaling.3 The IL-6 receptor is not regulated by NFkB and no
association was found with the SNP studied in IL6R.34
This could indicate that among patients with IBD, nonrespon-
ders to anti-TNF therapy are more likely to have an inﬂammatory
response mediated by other early pro-inﬂammatory cytokines
than TNF-a, such as IL-1b, IL-6 and IFN-g. This suggests that drugs
targeting IFN-g, IL-1b or IL-6 could potentially be useful for
treating patients who do not respond to anti-TNF therapy. This
interpretation is supported by the polymorphism in IL1RN, where a
genetically determined high inhibition of IL-1b signaling (high IL-
1RA level) was associated with beneﬁcial response. Furthermore,
this interpretation is also supported by another study that has
reported an association between the C-allele of rs1143634 in IL1B
and higher serum IL-1b level and a lower response rate to
inﬂiximab therapy among patients with CD.35
The variant allele of the 597T4C polymorphism in TLR2
(rs3804099) was associated with beneﬁcial response among
patients with CD, UC and IBD. The polymorphism has been shown
to decrease TNF-a level by B50%, IL-1b level by 75% and IL-6
level by 150%.36 In the light of the other results, we expected an
increased TNF-a level to be associated with beneﬁcial response
and an increased IL-1b and IL-6 levels to be associated with
nonresponse. This indicates that the relative levels of the
cytokines TNF-a, IL-1b and IL-6 are important in determining
response to anti-TNF.
The variant allele of the 197G4A polymorphism in IL17A was
associated with nonresponse among patients with UC and IBD.
The polymorphism has been shown to increase expression of IL-
17,37 indicating that high level of this cytokine may also be
associated with nonresponse.
The functional SNPs studied in IL4R, IL10, IL23R, TGFB1, PTPN22,
PPARG and NLRP3 were not associated with response to anti-TNF
therapy.
Overall, the results indicate that patients with genetically
determined high TNF-driven inﬂammatory response beneﬁt the
most from anti-TNF therapy. Conversely, patients with genetically
determined IL1B, IL6 and IFNG-driven inﬂammatory response
seem to beneﬁt the least from anti-TNF therapy. These patients
might beneﬁt from biological drugs targeting other cytokines such
as IL-1b, IL-6 or IFN-g or from a cocktail of several antibodies.
The results in this exploratory study should be interpreted with
care. Additional conﬁrmation of these ﬁndings in independent
cohorts should be performed before our results are applied in the
clinic. In the light of the obtained P-values and the number of
statistical tests performed, we cannot exclude that some of our
positive ﬁndings may be due to chance. We successfully
genotyped 37 polymorphisms. Of these, two polymorphisms
would be expected to be associated with treatment outcome by
pure chance assuming a 5% acceptance level. We found
numerous associated polymorphisms. Furthermore, most of the
found associations were biologically plausible. The study generally
did not have enough power to detect a recessive effect and the
associations were predominantly found to show gene-dose
effects. We cannot exclude that associations were not identiﬁed
due to insufﬁcient statistical power. On the other hand, this study
is rather large including 738 IBD patients treated with anti-TNF,
giving the cohort study 480% power to detect an OR of 1.6
assuming a minor allele frequency of 0.05. In addition, blood and
clinical data from these patients were collected at 18 large
gastroenterological centers at basic and specialized hospitals in
Denmark. Thus, the patients are representative of Danish patients
with severe IBD.
In conclusion, the results suggest that genes involved in the
regulation of NFkB through the TLR pathways, genes regulating
TNF-a signaling and cytokines regulated by NFkB are important
predictors for the response to anti-TNF therapy among patients
with IBD. Genetically strong TNF-mediated inﬂammatory response
was associated with beneﬁcial response to anti-TNF therapy. In
addition, patients with genetically determined high IL-1b, IL-6 or
IFN-g levels were less likely to respond, perhaps because the
colonic inﬂammation was primarily driven by these pro-inﬂam-
matory cytokines. This could indicate that the cytokines IL-1b, IL-6
and IFN-g may be potential targets for treating patients with IBD
who do not respond to anti-TNF therapy. Before the genetic
markers found in this study are applied in a clinical setting, they
should be conﬁrmed in independent cohorts.
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